Ipratropium Adultes Zentiva (Ipratropium Bromide)

Ipratropium bromide blocks muscarinic (M1 and M3) receptors on airway smooth muscle, preventing acetylcholine‑induced contraction. This inhibition reduces calcium influx, leading to relaxation of the bronchial muscles and resulting in bronchodilation without significant systemic anticholinergic activity.

The prescribed dose of Ipratropium Adultes Zentiva is determined by the treating physician based on the patient’s condition, severity, and response to therapy. The prescriber will specify the number of inhalations and frequency appropriate for each individual case.

Safety data for ipratropium bromide in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Ipratropium is an anticholinergic bronchodilator, whereas beta‑2 agonists (e.g., albuterol) stimulate adrenergic receptors to relax airway smooth muscle. Ipratropium is often used as an add‑on therapy for patients who need additional bronchodilation or who experience side effects from beta‑agonists. It has a different side‑effect profile, with less tachycardia but more anticholinergic symptoms such as dry mouth.

Store the inhalation solution at room temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight, and extreme temperatures. Do not freeze the product, and keep the container tightly closed when not in use to maintain sterility.

The medication is delivered via inhalation using a nebulizer or metered‑dose inhaler, as directed by the prescriber. Patients should follow the specific instructions for device preparation, inhalation technique, and cleaning to ensure optimal drug delivery and efficacy.

Serious risks include paradoxical bronchospasm, which can worsen breathing difficulty, and rare allergic reactions such as rash, angioedema, or anaphylaxis. If any signs of severe respiratory distress, swelling, or hypersensitivity occur, the medication should be discontinued immediately and medical attention sought.

Patients with a known hypersensitivity to ipratropium bromide or any component of the formulation should avoid its use. Caution is also advised for individuals with narrow‑angle glaucoma, urinary retention, or severe gastrointestinal obstruction, as anticholinergic effects may exacerbate these conditions.